Aug. 19, 2022
A new study has found that three drugs, including the antiparasitic ivermectin, had no significant effects in treating low oxygen levels or preventing ER visits, hospitalization or death due to COVID-19.
The research, published Thursday in the New England Journal of Medicine, compared the effectiveness of the Type 2 diabetes medication metformin, low-dose fluvoxamine, which is an antidepressant, and ivermectin as possible treatments against COVID-19 and long-term symptoms.
“None of the three medications that were evaluated prevented the occurrence of hypoxemia, an emergency department visit, hospitalization, or death associated with COVID-19,” the study says.
While the researchers say metformin may offer possible benefits in preventing ER visits, hospitalization and death, the results aren’t definitive without other studies.